|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation.
|
21988333 |
2012 |
|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Nonneuropathic amyloidoses (Ostertag type amyloidosis) include those due to abnormalities in lysozyme, fibrinogen Aalpha-chain, and apolipoprotein A-I and A-II.
|
16523055 |
2006 |
|
Amyloidosis, familial visceral
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Human lysozyme gene mutations cause hereditary systemic amyloidosis.
|
8464497 |
1993 |
|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Familial nephropathic non-neuropathic amyloidosis: clinical features, immunohistochemistry and chemistry.
|
1808634 |
1991 |
|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Amyloidosis, familial visceral
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Amyloidosis, familial visceral
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Kidney Diseases
|
0.140 |
Biomarker
|
group |
BEFREE |
An optimised liposomal formulation [DPPC/P-lyso-PC/DSPE-PEG2000 90/10/4 (mol/mol) (LTSL)] was chosen for further application in encapsulating therapeutic proteins, such as lysozyme and the brain-derived neurotrophic factor (BDNF), which are recognized as drug carriers and potential therapeutic agents for kidney diseases and neurological disorders.
|
28377318 |
2017 |
|
Kidney Diseases
|
0.140 |
AlteredExpression
|
group |
BEFREE |
Herein, a technique has been introduced for rapid visual detection of lysozyme, as its high level of excretion in biological fluids is a characteristic sign of leukemia and kidney disorders.
|
26452890 |
2015 |
|
Kidney Diseases
|
0.140 |
GeneticVariation
|
group |
BEFREE |
The patient had a mutation in the lysozyme gene characterized by substitution of the amino acid at position 64 in the mature protein from tryptophan to arginine, previously described in only 1 French family with prominent nephropathy.
|
12360495 |
2002 |
|
Kidney Diseases
|
0.140 |
GeneticVariation
|
group |
BEFREE |
We report a novel mutation (W64R) of the lysozyme that is associated with hereditary amyloidosis and prominent nephropathy.
|
11849445 |
2002 |
|
Kidney Diseases
|
0.140 |
Biomarker
|
group |
HPO |
|
|
|
|
Hypertensive disease
|
0.120 |
Biomarker
|
group |
BEFREE |
Interactions of leukocytes, in particular lysozyme M<sup>+</sup> (LysM<sup>+</sup>) monocytes, with the vessel wall play pivotal roles in promoting vascular dysfunction and arterial hypertension.
|
29364261 |
2018 |
|
Hypertensive disease
|
0.120 |
AlteredExpression
|
group |
LHGDN |
Our hypothesis--"high salivary lysozyme levels are associated with the odds of hypertension"--was confirmed.
|
18434581 |
2008 |
|
Hypertensive disease
|
0.120 |
Biomarker
|
group |
HPO |
|
|
|
|
Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Engaging Raman microscopy, we made a critical structural analysis of oligomer and other assembly structures of lysozyme obtained from hen egg white and, provided a quantitative estimation of protein secondary structure in different states of its fibrillation.
|
31820990 |
2020 |
|
Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bacopa monnieri inhibit hen egg white lysozyme fibrillation and help in retaining its activity at acidic condition.
|
31084353 |
2020 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structural changes of globular proteins and their resultant amyloid aggregation have been associated with various human diseases, such as lysozyme amyloidosis and light-chain amyloidosis.
|
31439662 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lysozyme is an amyloidogenic protein which is often used as a model protein for studying amyloidosis.
|
31276926 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An In Vitro elucidation of the antiaggregatory potential of Diosminover thermally induced unfolding of hen egg white lysozyme; A preventive quest for lysozyme amyloidosis.
|
30794897 |
2019 |
|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As there is no radical therapy for lysozyme amyloidosis, patients were given symptomatic treatment such as antihypertensive drugs and antibiotics.
|
31395023 |
2019 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Oral Ulcer
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome wide analysis for mouth ulcers identifies associations at immune regulatory loci.
|
30837455 |
2019 |
|
Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proline functionalized gold nanoparticles modulates lysozyme fibrillation.
|
30476794 |
2019 |
|
Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of Silica Nanoparticles on the Amyloid Fibrillation of Lysozyme.
|
31459377 |
2019 |